Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/03/13 | $33,000,000 | Series A |
Aisling Capital OrbiMed Advisors | undisclosed |
| 05/07/14 | $24,000,000 | Series B |
Aisling Capital OrbiMed Advisors | undisclosed |
